Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

SCYXBullishCorporate Developmentsnews

High materiality9/10

BARDA Contract Could Fund Up to $214 Million for SCY-247, Expanding SCYX Pipeline

Sep 28, 2026, 7:48 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Non-dilutive BARDA funding improves cash runway, signals political and regulatory support for SCYX’s antifungal program, and expands pipeline optionality, which could lift valuation. The risk remains that options are not exercised or clinical milestones slip, but the headline is meaningfully positive for fundamentals.

AI summary

What happened, with direct paths to the underlying reporting

SCYNEXIS announced BARDA funding to advance SCY-247 into Phase 2 for invasive candidiasis and prevention. The base award is about $18.5 million, with potential funding up to $214 million if options are exercised, enabling two indications NDA submissions. Management said SCY-770 milestones and the cash runway into 2029 remain unchanged.

SCYNEXIS announced BARDA funding to advance SCY-247 into Phase 2 for invasive candidiasis and prevention.
Base award about $18.5M; total potential funding up to $214M if options exercised.
Non-dilutive funding strengthens pipeline and reduces near-term dilution risk.
SCY-770 milestones and cash runway into 2029 remain unchanged.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.